1. Heteromeric P2X2/3 receptors are much more sensitive than homomeric P2X2 receptors to alphabeta-methylene-ATP, and this ATP analogue is widely used to discriminate the two receptors on sensory neurons and other cells. 2. We sought to determine the structural basis for this selectivity by synthesising ADP and ATP analogues in which the alphabeta and/or betagamma oxygen atoms were replaced by other moieties (including -CH2-, -CHF-, -CHCl-, -CHBr-, -CF2-, -CCl2-, -CBr2-, -CHSO3-, -CHPO3-, -CFPO3-, -CClPO3-, -CH2-CH2-, C triple bond C, -NH-, -CHCOOH-). 3. We tested their actions as agonists or antagonists by whole-cell recording from human embryonic kidney cells expressing P2X2 subunits alone (homomeric P2X2 receptors), or cells expressing both P2X2 and P2X3 subunits, in which the current through heteromeric P2X2/3 receptors was isolated. 4. ADP analogues had no agonist or antagonist effect at either P2X2 or P2X2/3 receptors. All the ATP analogues tested were without agonist or antagonist activity at homomeric P2X2 receptors, except betagamma-difluoromethylene-ATP, which was a weak agonist. 5. At P2X2/3 receptors, betagamma-imido-ATP, betagamma-methylene-ATP, and betagamma-acetylene-ATP were weak agonists, whereas alphabeta,betagamma- and betagamma,gammadelta-bismethylene-AP4 were potent full agonists. betagamma-Carboxymethylene-ATP and betagamma-chlorophosphonomethylene-ATP were weak antagonists at P2X2/3 receptors (IC50 about 10 microm). 6. The results indicate (a). that the homomeric P2X2 receptor presents very stringent structural requirements with respect to its activation by ATP; (b). that the heteromeric P2X2/3 receptor is much more tolerant of alphabeta and betagamma substitution; and (c). that a P2X2/3-selective antagonist can be obtained by introduction of additional negativity at the betagamma-methylene.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574118PMC
http://dx.doi.org/10.1038/sj.bjp.0705531DOI Listing

Publication Analysis

Top Keywords

p2x2/3 receptors
24
homomeric p2x2
16
atp analogues
12
heteromeric p2x2/3
12
p2x2 receptors
12
receptors
10
p2x2
8
p2x2 p2x2/3
8
cells expressing
8
expressing p2x2
8

Similar Publications

Article Synopsis
  • P2X3 and P2X2/3 receptor inhibitors are being targeted for pain relief, and this study reviews preclinical data on their effectiveness.
  • A meta-analysis of 67 articles revealed a significant overall pain reduction, particularly effective for visceral pain and mechanical hypersensitivity, with no notable differences based on sex or species.
  • The route of administration mattered: systemic methods were more effective than intrathecal, while intracerebroventricular methods worsened pain; overall, further clinical research is needed to translate these findings into treatments.
View Article and Find Full Text PDF
Article Synopsis
  • P2X receptors are important for sensory signaling and pain, functioning as cation channels activated by ATP, with their activation affected by Mg concentration and the binding of different ATP derivatives.
  • New fluorescently labelled ATP derivatives allow researchers to study how these receptors respond differently to various ligands, highlighting unique behaviors among P2X2, P2X3, and P2X2/3 receptors.
  • The research indicates that while magnesium influences P2X receptor activation, it still maintains strong binding, suggesting complex interactions that are critical for understanding the receptor's role in cellular signaling.
View Article and Find Full Text PDF

Aims: We report on investigations exploring the P2X3-receptor antagonist filapixant's effect on taste perception and cough-reflex sensitivity and describe its pharmacokinetics, including its CYP3A4-interaction potential.

Methods: In a randomized, placebo-controlled, double-blind study, 3 × 12 healthy men (18-45 years) were assigned (3:1) to filapixant (20, 80 or 250 mg by mouth) or placebo twice daily over 2 weeks. A single dose of midazolam (1 mg), a CYP3A4 substrate, was administered with and without filapixant.

View Article and Find Full Text PDF

Background And Purpose: The P2X3 receptor, a trimeric ionotropic purinergic receptor, has emerged as a potential therapeutic target for refractory chronic cough (RCC). Nevertheless, gefapixant/AF-219, the only marketed P2X3 receptor antagonist, might lead taste disorders by modulating the human P2X2/3 (hP2X2/3) heterotrimer. Hence, in RCC drug development, compounds exhibiting strong affinity for the hP2X3 homotrimer and a weak affinity for the hP2X2/3 heterotrimer hold promise.

View Article and Find Full Text PDF

Traditional Chinese medicine alleviating neuropathic pain targeting purinergic receptor P2 in purinergic signaling: A review.

Brain Res Bull

November 2023

Department of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China. Electronic address:

Past studies have suggested that Chinese herbal may alleviate neuropathic pain, and the mechanism might target the inhibition of purinergic receptor P2. This review discusses whether traditional Chinese medicine target P2 receptors in neuropathic pain and its mechanism in order to provide references for future clinical drug development. The related literatures were searched from Pubmed, Embase, Sinomed, and CNKI databases before June 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!